Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents

Frontiers in Oncology

Volumn 3 OCT, Issue , 2013, Pages

  Cesca, Marta ^a   Bizzaro, Francesca ^a   Zucchetti, Massimo ^a   Giavazzi, Raffaella ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Angiogenesis inhibitors; Combination therapies; Drug delivery; Paclitaxel; Tumor microenvironment; Tyrosine kinase receptor inhibitors; Vascular disrupting agents

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; BRIVANIB; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBRONECTIN; FLUORODEOXYGLUCOSE; FLUOROURACIL; GEMCITABINE; HOE 33342; IMATINIB; INTERLEUKIN 2; N ACETYLCOLCHINOL PHOSPHATE; ORANTINIB; PACLITAXEL; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR; RABEPRAZOLE; SORAFENIB; SUNITINIB; TRASTUZUMAB; VANDETANIB; VASCULAR TARGETING AGENT; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER TISSUE; CAPILLARY DENSITY; CELL PROLIFERATION; COLORECTAL CANCER; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG UPTAKE; HUMAN; HYPOXIA; LUNG NON SMALL CELL CANCER; MICROTUBULE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 84891060305     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00259     Document Type: Article

References (75)

1. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov (2007) 6:273-86. doi: 10.1038/nrd2115
2. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature (2011) 473:298-307. doi:10.1038/nature10144
3. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature (2005) 438:967-74. doi:10.1038/nature04483
4. Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol (2009) 6:395-404. doi:10.1038/nrclinonc.2009.52
5. Matrana MR, Atkinson B, Jonasch E, Tannir NM. Emerging targeted therapies in metastatic renal cell carcinoma. Curr Clin Pharmacol (2011) 6:189-98. doi:10.2174/157488411797189398
6. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer (2005) 5:423-35. doi:10.1038/nrc1628
7. Giavazzi R, Bani MR, Taraboletti G. Tumor-host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds. Cancer Metastasis Rev (2007) 26:481-8. doi:10.1007/s10555-007-9074-y
8. Spear MA, Lorusso P, Mita A, Mita M. Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic. Curr Drug Targets (2011) 12:2009-15. doi:10.2174/138945011798829366
9. Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol (2005) 23:1295-311. doi:10.1200/JCO.2005.10.022
10. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 350:2335-42. doi:10.1056/NEJMoa032691
11. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 355:2542-50. doi:10.1056/NEJMoa061884
12. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med (2011) 365:2473-83. doi:10.1056/NEJMoa1104390
13. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 365:2484-96. doi:10.1056/NEJMoa1103799
14. Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol (2013) 14:236-43. doi:10.1016/S1470-2045(12)70567-3
15. Jonasch E, Tannir NM. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Cancer J (2008) 14:315-9. doi:10.1097/PPO.0b013e31818675d4
16. Scagliotti G, Novello S, Von Pawel J, Reck M, Pereira JR, Thomas M, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 28:1835-42. doi:10.1200/JCO.2009.26.1321
17. Teicher BA. A systems approach to cancer therapy (antioncogenics + standard cytotoxics ? mechanism(s) of interaction). Cancer Metastasis Rev (1996) 15:247-72. doi:10.1007/BF00437479
18. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer (2006) 6:583-92. doi:10.1038/nrc1893
19. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev (2005) 15:102-11. doi:10.1016/j.gde.2004.12.005
20. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med (2003) 9:713-25. doi:10.1038/nm0603-713
21. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med (2001) 7:987-9. doi:10.1038/89889
22. Hagendoorn J, Tong R, Fukumura D, Lin Q, Lobo J, Padera TP, et al. Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. Cancer Res (2006) 66:3360-4. doi:10.1158/0008-5472.CAN-05-2655
23. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 91:1071-121. doi:10.1152/physrev.00038.2010
24. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol (2013) 31:2205-18. doi:10.1200/JCO.2012.46.3653
25. Franco M, Man S, Chen L, Emmenegger U, Shaked Y, Cheung AM, et al. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res (2006) 66:3639-48. doi:10.1158/0008-5472.CAN-05-3295
26. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer (2008) 8:579-91. doi:10.1038/nrc2403
27. Cesca M, Frapolli R, Berndt A, Scarlato V, Richter P, Kosmehl H, et al. The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma. Neoplasia (2009) 11:1155-64.
28. Marcucci F, Corti A. How to improve exposure of tumor cells to drugs: promoter drugs increase tumor uptake and penetration of effector drugs. Adv Drug Deliv Rev (2012) 64:53-68. doi:10.1016/j.addr.2011.09.007
29. Moschetta M, Cesca M, Pretto F, Giavazzi R. Angiogenesis inhibitors: implications for combination with conventional therapies. Curr Pharm Des (2010) 16:3921-31. doi:10.2174/138161210794455021
30. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov (2004) 3:391-400. doi:10.1038/nrd1381
31. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A (1996) 93:14765-70. doi:10.1073/pnas.93.25.14765
32. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell (2004) 6:553-63. doi:10.1016/j.ccr.2004.10.011
33. Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer (2003) 88:1979-86. doi:10.1038/sj.bjc.6601005
34. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res (2007) 13:3942-50. doi:10.1158/1078-0432.CCR-07-0278
35. Oliva P, Decio A, Castiglioni V, Bassi A, Pesenti E, Cesca M, et al. Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models. Br J Cancer (2012) 107:360-9. doi:10.1038/bjc.2012.261
36. Morosi L, Spinelli P, Zucchetti M, Pretto F, Carra A, D'Incalci M, et al. Determination of Paclitaxel distribution in solid tumors by nano-particle assisted laser desorption ionization mass spectrometry imaging. PLoS ONE (2013) 8:e72532. doi:10.1371/journal.pone.0072532
37. Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S, et al. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther (2012) 11:752-62. doi:10.1158/1535-7163.MCT-11-0742-T
38. Hurvitz S, Pegram M, Lin L, Chan D, Allen H, Dichmann R, et al. Final results of a phase II trial evaluating trastuzumab and bevacizumab as first line treatment of HER2-amplified advanced breast cancer. Cancer Res (2009) 69(Suppl):6094. doi:10.1158/0008-5472.SABCS-09-6094
39. Willett CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 10:145-7. doi:10.1038/nm988
40. Van der Veldt AA, Lubberink M, Bahce I, Walraven M, De Boer MP, Greuter HN, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell (2012) 21:82-91. doi:10.1016/j.ccr.2011.11.023
41. Van der Veldt AA, Lammertsma AA, Smit EF. Scheduling of anticancer drugs: timing may be everything. Cell Cycle (2012) 11:4339-43. doi:10.4161/cc.22187
42. Rovida A, Castiglioni V, Decio A, Scarlato V, Scanziani E, Giavazzi R, et al. Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice. Mol Cancer Ther (2013). doi:10.1158/1535-7163.MCT-13-0244. [Epub ahead of print].
43. Ma J, Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther (2008) 7:3670-84. doi:10.1158/1535-7163.MCT-08-0715
44. Ma J, Waxman DJ. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol Cancer Ther (2008) 7:79-89. doi:10.1158/1535-7163.MCT-07-0584
45. Fenton BM, Paoni SF. The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature. Cancer Res (2007) 67:9921-8. doi:10.1158/0008-5472.CAN-07-1066
46. Ma J, Chen CS, Blute T, Waxman DJ. Antiangiogenesis enhances intratumoral drug retention. Cancer Res (2011) 71:2675-85. doi:10.1158/0008-5472.CAN-10-3242
47. Garofalo A, Naumova E, Manenti L, Ghilardi C, Ghisleni G, Caniatti M, et al. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin Cancer Res (2003) 9:3476-85.
48. Naumova E, Ubezio P, Garofalo A, Borsotti P, Cassis L, Riccardi E, et al. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Clin Cancer Res (2006) 12:1839-49. doi:10.1158/1078-0432.CCR-05-1615
49. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res (1996) 2:1843-9.
50. Troiani T, Serkova NJ, Gustafson DL, Henthorn TK, Lockerbie O, Merz A, et al. Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. Clin Cancer Res (2007) 13:6450-8. doi:10.1158/1078-0432.CCR-07-1094
51. Bello E, Taraboletti G, Colella G, Zucchetti M, Forestieri D, Licandro SA, et al. The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts. Mol Cancer Ther (2013) 12:131-40. doi:10.1158/1535-7163.MCT-12-0275-T
52. Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res (2002) 62:5476-84.
53. Vlahovic G, Ponce AM, Rabbani Z, Salahuddin FK, Zgonjanin L, Spasojevic I, et al. Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br J Cancer (2007) 97:735-40. doi:10.1038/sj.bjc.6603941
54. Teicher BA, Dupuis NP, Robinson MF, Emi Y, Goff DA. Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Oncol Res (1995) 7:237-43.
55. Maione F, Molla F, Meda C, Latini R, Zentilin L, Giacca M, et al. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J Clin Invest (2009) 119:3356-72. doi:10.1172/JCI36308
56. Maione F, Capano S, Regano D, Zentilin L, Giacca M, Casanovas O, et al. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J Clin Invest (2012) 122:1832-48. doi:10.1172/JCI58976
57. Escorcia FE, Henke E, McDevitt MR, Villa CH, Smith-Jones P, Blasberg RG, et al. Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res (2010) 70:9277-86. doi:10.1158/0008-5472.CAN-10-2029
58. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res (2004) 10:415-27. doi:10.1158/1078-0432.CCR-0642-03
59. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer (2005) 5:436-46. doi:10.1038/nrc1627
60. Skliarenko JV, Lunt SJ, Gordon ML, Vitkin A, Milosevic M, Hill RP. Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors. Cancer Res (2006) 66:2074-80. doi:10.1158/0008-5472.CAN-05-2046
61. Patterson DM, Rustin GJ. Vascular damaging agents. Clin Oncol (R Coll Radiol) (2007) 19:443-56. doi:10.1016/j.clon.2007.03.014
62. Chaplin DJ, Horsman MR, Siemann DW. Current development status of small-molecule vascular disrupting agents. Curr Opin Investig Drugs (2006) 7:522-8.
63. Martinelli M, Bonezzi K, Riccardi E, Kuhn E, Frapolli R, Zucchetti M, et al. Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. Br J Cancer (2007) 97:888-94.
64. Goto H, Yano S, Matsumori Y, Ogawa H, Blakey DC, Sone S. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin. Clin Cancer Res (2004) 10:7671-6. doi:10.1158/1078-0432.CCR-04-1171
65. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell (2008) 14:263-73. doi:10.1016/j.ccr.2008.08.001
66. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer (2004) 4:253-65. doi:10.1038/nrc1317
67. Moschetta M, Pretto F, Berndt A, Galler K, Richter P, Bassi A, et al. Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts. Cancer Res (2012) 72:1814-24. doi:10.1158/0008-5472.CAN-11-1919
68. Frey K, Schliemann C, Schwager K, Giavazzi R, Johannsen M, Neri D. The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma. J Urol (2010) 184:2540-8. doi:10.1016/j.juro.2010.07.030
69. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med (2013) 64:15-29. doi:10.1146/annurev-med-050311-201823
70. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res (1999) 59:3776-82.
71. Bronstad A, Berg A, Reed RK. Effects of the taxanes paclitaxel and docetaxel on edema formation and interstitial fluid pressure. Am J Physiol Heart Circ Physiol (2004) 287:H963-8. doi:10.1152/ajpheart.01052.2003
72. Taghian AG, Abi-Raad R, Assaad SI, Casty A, Ancukiewicz M, Yeh E, et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J Clin Oncol (2005) 23:1951-61. doi:10.1200/JCO.2005.08.119
73. Zhang DS, Wang DS, Wang ZQ, Wang FH, Luo HY, Qiu MZ, et al. Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer. Cancer Chemother Pharmacol (2013) 71:1065-72. doi:10.1007/s00280-013-2102-4
74. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol (2011) 29:4548-54. doi:10.1200/JCO.2011.36.5742
75. Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov (2012) 2:260-9. doi:10.1158/2159-8290.CD-11-0242